Question 1

What amounts of BAM15 did the published studies use?

Accepted Answer

The figures below are study parameters, reported as such, and the unit changes with the experiment. The 2023 diabetic-mouse study compared calorie restriction against BAM15 at two doses of 0.1% and 0.2% (w/w) admixed in diet, with one group also fed only within a set window. The 2025 side-by-side comparison of 15 uncouplers used a similar pair, feeding mice chow with 0.15% BAM15 (w/w) or chow with 0.2% BAM15 (w/w). The 2022 muscle-ageing study used the lower end, giving aged obese mice BAM15 at 0.1% w/w in high fat diet for ten weeks. Away from the food-based designs, a 2025 artery study evaluated BAM15 at 5 mg/kg/day given under the skin in mice. Those are the four designs that recur. Everything else in this literature is a cell-culture concentration.

Question 2

Who received those amounts?

Accepted Answer

Mice, almost entirely, and mice chosen for a disease rather than for being ordinary. The 2023 study used male db/db mice, a strain carrying a genetic fault that produces severe hyperglycemia, obesity, hypertriglyceridemia, and fatty liver. The 2022 muscle study worked at the other end of life, randomising eighty-week-old male C57BL/6J mice with obesity to ten weeks of treatment. Other species appear at the edges of the literature: a 2022 ageing study gave 50 µM BAM15 to nematode worms, and a 2020 imaging experiment infused it into two pigs. Reading an amount without reading who received it is how a mouse figure becomes a human protocol. Every number on this page belongs to an animal with a named strain, a named diet and a named illness.

Question 3

Why is the amount a percentage rather than a milligram figure?

Accepted Answer

Because the compound was mixed into food rather than given as a measured dose, and that is a deliberate choice rather than sloppiness. A percentage by weight, written w/w, means grams of BAM15 per hundred grams of diet, as in the 2024 fatty-liver study where treatments were admixed in diet and mice were pair-fed to control for drug intake. Pair-feeding means each treated animal gets the same quantity of food as its control, so differences cannot be explained by one group eating more. The design suits what an uncoupler does, because the 2020 obesity work found that BAM15 reduced body fat in mice without altering food intake, which keeps the delivered quantity steady across groups. The consequence for a reader is blunt. A figure expressed as a share of a rodent's diet has no equivalent outside that cage, and converting it would mean inventing the mouse's appetite, its weight and its absorption.

Question 4

How was BAM15 administered?

Accepted Answer

Three routes appear, and the choice follows the question being asked rather than any judgement about which works best. Giving it by mouth dominates the metabolic work. That is possible because the 2020 obesity study found that BAM15 is orally bioavailable, which means enough of it survives the gut to reach the blood. The 2025 artery study used a shot under the skin, written s. c. in the paper, with the full figure recorded as 5 mg/kg/day. A 2023 sepsis study injected it at fixed intervals instead, giving mice BAM15 at 0, 6, or 12 hours after the surgical procedure that induced illness. A 2025 tumour study kept it local, reporting intratumoral injection of 50 ng/mL BAM15, which means a shot into the tumour itself. A strength injected into a lump of tissue is not the same kind of number as a daily amount eaten for weeks, although both get reported as doses.

Question 5

How long did the studies run?

Accepted Answer

Weeks, in the metabolic work, and the two commonest durations are four and ten. The 2025 comparison phenotyped its mice over 4 weeks of treatment before analysing tissue and plasma. The 2024 fatty-liver study ran its animals on a fattening diet for 38 weeks before stratification and randomization to treatments for 8 weeks. The longest BAM15 exposure covered here is the muscle-ageing experiment's ten weeks of high fat diet in mice already eighty weeks old. Ten weeks in an aged mouse is a substantial fraction of what remains of its life, which is why that study carries weight. It is still ten weeks, and nothing covered here describes a year.

Question 6

Did more produce more?

Accepted Answer

In the diabetic-mouse work, partly, and the shape of the answer is more interesting than a yes. In those mice, the 2023 study found that low-dose 0.1% BAM15 did not affect body mass but partially improved glucose tolerance to a similar degree as 50% calorie restriction. Its own conclusion draws the line: the smaller amount showed that the gains in glucose control are independent of weight loss. The 2025 comparison saw the same pattern, reporting that BAM15 dose-dependently improved body weight and metabolic parameters in db/db mice, with the larger share of food doing more across weight, glucose and liver measures. Two amounts is not a curve. What those studies show is that the smaller amount did something different from the larger one, and not where any ceiling sits.

Question 7

Is there a BAM15 dosage chart?

Accepted Answer

Not one built from this literature, and a chart assembled honestly from it would be unusable as a protocol. It would have four rows, three of them expressed as a percentage of mouse chow, one as milligrams per kilogram injected under the skin of a mouse, and a column headed species that read mouse all the way down. Charts are also harder to justify in this class than in most, because a 2025 comparison of 15 uncouplers concluded that mitochondrial uncouplers should not be generalized and each uncoupler molecule needs to be considered by its own actions in well-defined experimental conditions. If one uncoupler's numbers cannot be read across to another, a figure copied out of a mouse study certainly cannot be read across to a person. A chart that leaves the species column off is not simplifying the evidence, it is deleting it.

Question 8

Is there a human amount?

Accepted Answer

No study among the research behind this page gave BAM15 to a person, so there is no human amount to report, and the nearest approaches show how far off that is. The closest is a 2020 imaging study whose preliminary dose response experiments were conducted in two pigs, infusing BAM15 into the heart arteries to shift a radioactive tracer. The authors describe what they were measuring, reporting a maximum depolarization of 10 mV as a result of the BAM15 infusion. That is an imaging endpoint in an anaesthetised animal, not a therapeutic amount, and it was delivered into a coronary artery rather than swallowed. Describing it as the human-adjacent figure would overstate it twice over.

Question 9

Can an animal amount be converted?

Accepted Answer

Not here, and refusing the conversion is a position about the evidence rather than caution for its own sake. Two of the three published routes do not have a quantity to convert in the first place, since a percentage of chow and a concentration in a tumour both describe an environment rather than a dose to a body. Even the molecule's distribution refuses the simplification, because a 2021 study tracked where it went and found BAM15 in adipose, liver, and tumor tissue with low abundance in skeletal muscle in mice. A compound that concentrates in fat and liver in one species does not necessarily do so in another, and body-surface-area arithmetic has nothing to say about that. Any figure produced that way would be a recommendation wearing a calculation.

Question 10

Does the form it is in change the amount needed?

Accepted Answer

Substantially, and this is one of the few places where this literature is unusually clear. A 2022 formulation study built albumin nanoparticles precisely because they improve aqueous solubility and half-life of BAM15, which is to say the plain molecule dissolves badly and leaves quickly. A 2023 sepsis study found the packaging changed the result as well, reporting that BAM15 particles but not free BAM15 alleviated liver injury induced by a bacterial toxin in mice. That second finding is the important one. Same molecule, same animals, different carrier, and one worked where the other did not. An amount is therefore inseparable from the preparation it was given in, and none of the preparations in these studies is what material sold under this name would be.

Question 11

Why do the published amounts differ so much?

Accepted Answer

Because the experiments were asking unrelated questions, and each one chose the delivery that suited its own endpoint. A metabolic study needs steady exposure over weeks, which is why the 2025 comparison benchmarked its uncouplers against a lifestyle intervention of 35% calorie restriction in mice. A cancer study needs the compound where the tumour is, which is why a 2025 paper used local injection and reported that low-dose BAM15 promoted signalling and the TCA cycle without increasing cell proliferation or inducing cell death in vitro. A sepsis study needs timing above all, which is why the 2023 kidney work gave it at three separate points and found BAM15 reduced mortality, even after 12 hours, when mice were ill. The spread in the numbers is therefore not disagreement about an amount. It is four different experimental questions, and none of them was what quantity a person should take.

Question 12

Does any of this apply to material bought under this name?

Accepted Answer

No, and the gap is wider than it would be for most compounds covered on this site. Every figure above describes a compound of verified structure, weighed into a known quantity of diet or dissolved to a known concentration by the people who synthesised it. Structure is not a technicality in this class, since the 2015 chemistry paper showed the importance of the furazan, pyrazine, and aniline rings as well as pKa in maintaining its effective protonophore activity. No analysis among the research behind this page has measured what is inside any vial sold under this name, so neither its identity nor its strength can be checked against the figures above. What is documented about harm, and what the older uncouplers did to people, is taken apart on the BAM15 safety page. What the animal amounts actually produced is on the BAM15 benefits page, and the wider picture is on the BAM15 overview.

Study	Animal	Amount studied	How given
2023 diabetic-mouse study	Diabetic mice	0.1% or 0.2% w/w	Mixed into the diet
2025 comparison of 15 uncouplers	Mice	0.15% or 0.2% w/w	Mixed into chow
2022 muscle-ageing study	Aged obese mice	0.1% w/w	In high fat diet for ten weeks
2025 artery study	Mice	5 mg/kg/day	Under the skin

BAM15 protocols in the published literature